by Brian Rivera and Dr. Bryan Tackett, Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. Improved reliability to synthetic routes coupled with new drug delivery technologies has given a heightened level of interest in these clinically interesting targets. However, characterization of oligos, specifically by ion-pair reversed phase liquid chromatography (IP-RPLC), can be quite challenging.
Most oligos are manufactured by solid phase synthesis, where nucleotides are added in a step-wise phase, leading to characterization of the commonly associated n-1 and n+1 impurities. However, even with ion-pair to facilitate the analytical separation, for full characterization of process and product related impurities for synthetic oligonucleotides, extensive method development and mobile phase optimization is required.
Download the full whitepaper by simply hitting the 'Download Now' link at the top of the page.
